You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行》瑞銀:科倫博泰(06990.HK)中期收入遜預期 維持「買入」評級
阿思達克 08-19 10:53
瑞銀發表研究報告指,科倫博泰生物(06990.HK)上半年收入為9.5億元人民幣,按年下跌31%,低於該行預期的11億元人民幣,但符合市場普遍預期的9.33億元人民幣。期內淨虧損1.45億元人民幣,大致符合該行預測的1.36億元人民幣,好過市場預期的虧損3.3億元人民幣。 瑞銀指,科倫博泰的核心產品蘆康沙妥珠單抗(sac-TMT)已進入逾1,000間醫院,並與超過400間DTP藥房合作,管理層預期隨著市場滲透率提升及新適應症批准,下半年銷售將顯著增長,維持全年產品銷售額達到8億至10億元人民幣的目標。 該行將sac-TMT今年銷售預測從10億元人民幣下調至8.5億元人民幣,同時下調費用預測,基於全球研發潛力及關鍵數據可見度,將其海外銷售高峰預測從650億元人民幣上調至750億元人民幣,相應將目標價從452.8元上調至519元,維持「買入」評級。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account